Reducing the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) who are managed with percutaneous coronary intervention (PCI). This includes patients with unstable angina (UA), non-ST-elevation myocardial infarction (NSTEMI), or ST-elevation myocardial infarction (STEMI).
Prasalse contains Prasugrel, an antiplatelet agent that helps prevent the formation of blood clots. It works by inhibiting platelet activation and aggregation through irreversible binding to the P2Y12 class of ADP receptors on platelets. This reduces the risk of heart attack or stroke in patients with acute coronary syndrome (ACS) who are undergoing percutaneous coronary intervention (PCI).